Key result
S100A1 gene therapy preserves LV function and reduces cardiac hypertrophy post-MI in rats.
Why the study?
Does S100A1 gene therapy preserve global heart function in rats after myocardial infarction?
Population
Rats with cryothermia-induced myocardial infarction
Comparison
In vivo intracoronary delivery of S100A1… vs Saline, control adenovirus, or sham operation
Design
Preclinical
Follow-up
1 week
Authors
Loading...
Hypothesis-generating in rat MI model; leaves open translation of S100A1 gene therapy to clinical use.
Does S100A1 gene therapy preserve global heart function in rats after myocardial infarction?
S100A1 gene therapy preserves global LV function and reduces cardiac hypertrophy in a rat model of myocardial infarction, suggesting a potential novel treatment strategy.
Pleger et al. (2005) studied Myocardial infarction. S100A1 gene therapy vs. Saline, control adenovirus (AdGFP), or sham operation was evaluated on Global in vivo LV function. S100A1 gene therapy preserved global in vivo left ventricular function and reduced cardiac hypertrophy 1 week after myocardial infarction in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: